News

2018

Sanofi Ventures

July 10, 2018 - Sanofi doubles its participation in two funds dedicated to innovation

View PDF 

  

Navitor Pharmaceuticals

June 26, 2018 - Navitor Pharmaceuticals Initiates a Clinical Study of NV‐5138, a Novel, Oral Small Molecule for Treatment‐
Resistant Depression

View PDF 

 

Unum Therapeutics

June 25, 2018 - Unum Therapeutics Joins Russell 3000 Index

View PDF 

 

Immune Design

June 25, 2018 - Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell
Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma

View PDF 

 

Omada Health

June 20, 2018 - Omada Health Adds New Programs for Type 2 Diabetes and Hypertension Self-Management

View PDF 

 

 

Inozyme Pharma

June 13, 2018 - Inozyme Pharma Offers No-Cost Genetic Testing for Rare Calcification Disorders

View PDF 

 

 

Science 37

May 31, 2018 - Sanofi Ventures Portfolio Company Science 37 is Ranked as Entrepreneur's Top 20 Companies to Watch for 2018

Link

 

 

Immune Design

May 24, 2018 - Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma

View PDF 

 

 

Unum Therapeutics

May 14, 2018 - Unum Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update

View PDF 

 

 

Ovid Therapeutics

May 8, 2018 - Ovid Therapeutics Reports First Quarter 2018 Financial Results and Corporate Progress

View PDF 

 

 

Immune Design

May 2, 2018 - Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update

View PDF 

 

 

Common Sensing

April 11, 2018 - Common Sensing Secures $6.6M Series A Investment Round to Support Injectable Medicines

View PDF 

 

 

Unum Therapeutics

April 3, 2018 - Unum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle Genetics

View PDF 

 

 

Immune Design

March 12, 2018 - Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma

View PDF 

 

 

Expansion Therapeutics

January 3, 2018 - Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases  

View PDF 

 

2017

Ovid Therapeutics

December 20, 2017 - Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut Syndrome

View PDF 

 

 

Ovid Therapeutics

December 19, 2017 - Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome

View PDF 

 

 

Curisium

December 14, 2017 - Curisium Raises $3.5M to Scale Innovative Healthcare Contracting on Blockchain

View PDF 

 

Ovid Therapeutics

December 5, 2017 - Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome

View PDF 

 

Ovid Therapeutics

December 3, 2017 - Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting

View PDF 

 

Ovid Therapeutics

November 28, 2017 - Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents

View PDF 

 

Inozyme Pharma

November 15, 2017 - Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone

View PDF 

 

Immune Design

October 19, 2017 - Immune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’s Lymphoma

View PDF 

 

Ovid Therapeutics

October 16, 2017 - Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model

View PDF 

 

Immune Design

October 16, 2017 - Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients

View PDF 

 

Ovid Therapeutics

October 5, 2017 - Ovid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop

View PDF 

  

Immune Design

September 8, 2017 - New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response

View PDF 

 

Ovid Therapeutics

September 6, 2017 - Ovid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel

View PDF 

 

Immune Design

August 30, 2017 - Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress

View PDF 

 

Ovid Therapeutics

August 21, 2017 - Ovid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies

View PDF 

 

Ovid Therapeutics

August 10, 2017 - Ovid Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Progress

View PDF 

 

Evidation Health

July 31, 2017 - Sanofi Strengthens Ties with Evidation Health, Leader in Quantifying Health Behaviors

View PDF 

 

NeuroVia

July 20, 2017 - NeuroVia Closes Series A Financing Round of $14M to Develop Novel Treatment Option for X-ALD Disease

View PDF 

 

Ovid Therapeutics

June 23, 2017 - Ovid Therapeutics to be Added to Russell 2000®, 3000® and Microcap® Indexes

View PDF 

 

Omada Health

June 14, 2017 - Omada Health Raises $50 Million, Led by Cigna

View PDF 

 

Ovid Therapeutics

June 13, 2017 - Ovid Therapeutics Reports First Quarter 2017 Financial Results and Recent Corporate Progress

View PDF 

 

Immune Design

May 17, 2017 - Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update

View PDF 

 

Immune Design

May 17, 2017 - New Clinical and Biomarker Data Validate Immune Design's Lead Programs and Discovery Platforms

View PDF 

 

Evidation Health

April 27, 2017 - Evidation Health secures Financing from Sanofi-Genzyme BioVentures to Fuel Commercial Growth

View PDF 

 

Science 37

April 25, 2017 - Science 37 Raises $29M To Bring Clinical Trials Directly Into Patients' Homes

View PDF

 

Ovid Therapeutics

April 10, 2017 - Ovid Therapeutics Announces Initiation of Phase 1 Clinical Trial of OV101 for Adolescents with Angelman Syndrome or Fragile X Syndrome

View PDF

 

GlycoMimetrics

March 7, 2017 - GlycoMimetrics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271

View PDF

 

Science 37

March 1, 2017 - Science 37 and Sanofi Introduce a New Partnership

View PDF

 

Immune Design

March 7, 2017 - Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update.

View PDF

 

Immune Design

March 1, 2017 - Immune Design To Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at AACR Annual Meeting 2017.

View PDF

 

Immune Design

February 22, 2017 - Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate

View PDF

 

Ovid Therapeutics

February 9, 2017 - Ovid Therapeutics Announces First Patient Randomized in the Phase 2 STARS Clinical Trial in Adults with Angelman Syndrome

View PDF

 

Ovid Therapeutics

February 9, 2017 - Ovid Therapeutics and NeuroPointDX Announce Collaboration to Identify Biomarkers for Angelman

View PDF

 

Ovid Therapeutics

January 19, 2017 - Ovid Therapeutics Names Jacqueline A. French, M.D. to Scientific Advisory Board

View PDF

 

Ovid Therapeutics

January 18, 2017 - Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies

View PDF

 

Lysosomal Therapeutics

January 9, 2017 - Allergan Enters Parkinson's Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-in-Class Breakthrough Compounds

View PDF